Mark Elliott Boulding Sells 1,543 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 1,543 shares of PTC Therapeutics stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total value of $69,959.62. Following the sale, the vice president now owns 108,846 shares in the company, valued at $4,935,077.64. This trade represents a 1.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Mark Elliott Boulding also recently made the following trade(s):

• On Monday, December 2nd, Mark Elliott Boulding sold 85,600 shares of PTC Therapeutics stock. The stock was sold at an average price of $52.26, for a total value of $4,473,456.00.

PTC Therapeutics Price Performance

Shares of NASDAQ:PTCT opened at $43.94 on Friday. The firm has a fifty day moving average price of $45.19 and a two-hundred day moving average price of $38.47. The company has a market cap of $3.39 billion, a price-to-earnings ratio of -7.40 and a beta of 0.62. PTC Therapeutics, Inc. has a one year low of $23.58 and a one year high of $54.16.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. The Goldman Sachs Group raised their price objective on shares of PTC Therapeutics from $32.00 to $42.00 and gave the stock a “sell” rating in a report on Wednesday, December 4th. Robert W. Baird raised their price target on shares of PTC Therapeutics from $52.00 to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 3rd. Royal Bank of Canada raised PTC Therapeutics from a “sector perform” rating to an “outperform” rating and increased their price objective for the company from $39.00 to $63.00 in a report on Tuesday, December 3rd. JPMorgan Chase & Co. boosted their target price on PTC Therapeutics from $51.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, November 19th. Finally, Barclays increased their price target on PTC Therapeutics from $45.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 3rd. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $54.08.

Institutional Investors Weigh In On PTC Therapeutics

Large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its holdings in shares of PTC Therapeutics by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 116,396 shares of the biopharmaceutical company’s stock valued at $3,559,000 after acquiring an additional 7,314 shares in the last quarter. Arizona State Retirement System increased its position in shares of PTC Therapeutics by 3.4% in the second quarter. Arizona State Retirement System now owns 19,301 shares of the biopharmaceutical company’s stock worth $590,000 after purchasing an additional 636 shares during the last quarter. Quest Partners LLC purchased a new stake in PTC Therapeutics in the second quarter valued at approximately $128,000. Choreo LLC lifted its position in PTC Therapeutics by 4.1% during the second quarter. Choreo LLC now owns 11,426 shares of the biopharmaceutical company’s stock valued at $356,000 after purchasing an additional 452 shares during the last quarter. Finally, Headlands Technologies LLC grew its stake in PTC Therapeutics by 83.2% in the 2nd quarter. Headlands Technologies LLC now owns 6,611 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 3,002 shares in the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.